809 results about "Glucose lowering" patented technology

Reducing the digestion of digestible carbohydrates in a digestible carbohydrate-based material, and reducing the absorption of the digestion product(s) of digestible carbohydrates (that is, simple sugars) within the small intestine. The undigested digestible carbohydrate and the unabsorbed digestion products pass through the small intestines and into the colon, where they are fermented. In effect, the food materials made by practicing the present invention cause a controlled amount of digestible carbohydrate to by-pass the small intestine, resulting in the fermentation of digestible carbohydrates in the colon. The invention also provides for processing of a digestible carbohydrate-based ingredient with a non-digestible food film material, to form a reduced digestible carbohydrate food having a protective food film network, which can inhibit or prevent digestion of the digestible carbohydrate. The present invention also provides for processing of a digestible carbohydrate-based ingredient with a non-digestible food film material, to provide a resulting reduced digestible carbohydrate food containing a viscosity-building component that contributes to the formation of a viscous intestinal chyme that can inhibit or prevent digestion of the digestible carbohydrate and can inhibit adsorption of digestion products of digestible carbohydrates in the small intestine.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol / L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol / L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and / or regulation of gastric emptying, such as diabetes and eating disorders.

Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention provides a health-care food capable of stabilizing the glucose function after meal. The food refers to health-care noodles, health-care rice, health-care porridge and health-care flour which are prepared from embedding and fixing a variety of coarse cereals of rice, flour, fungus and coenzyme by marine organisms and has the slow-release glucose-lowering function. The invention is characterized by pure natural materials and obvious glucose-lowering function.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention relates to a food, in particular to a yogurt manufacturing method, more particularly to a yogurt for assisting to reduce the blood sugar, and a production method thereof. The product comprises skimmed fresh milk, water-soluble dietary fiber, xylitol, lactoalbumin, stabilizer, aspartame, acesulfame potassium, trivalent chromium, streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus. The trivalent chromium for reducing the blood sugar is added in the yogurt, thereby the product plays the role of reducing the blood sugar, and not only has the abundant nutrition, but also plays the role of health care for assisting to reduce the blood sugar when the consumers with diabetes drink the yogurt. The product is effective after clinical test and has higher security.

PCT No. PCT / KR97 / 00133 Sec. 371 Date May 4, 1999 Sec. 102(e) Date May 4, 1999 PCT Filed Jul. 2, 1997 PCT Pub. No. WO98 / 00389 PCT Pub. Date Jan. 8, 1998This invention relates to a novel 2-hydroxypropionic acid derivative and its manufacturing method. Based on its mechanism to inhibit the CPT I, 2-hydroxypropionic acid derivative of this invention has blood glucose lowering effects so that the derivative may be effectively used as an antidiabetic agent having remarkable antidiabetic activity and fewer side effects.

The present invention belongs to the field of medicine, and particularly relates to a novel curcumin pharmaceutical preparation, which comprises a solid dispersion, a micellar preparation, SMEDDS and a nanometer emulsion. According to the present invention, by increasing the solubility and the bioavailability of curcumin, the curcumin pharmaceutical preparation can effectively utilize the pharmacological effects of anti-oxidation, anti-inflammation, anti-cancer, apoptosis induction, antiangiogenesis, neuroprotection, anti-microorganism, liver and kidney protection, vascular formation inhibition, myocardial infarction prevention, blood glucose lowering, anti-rheumatism and the like of the curcumin.

Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

A composition is provided which contains policosanol and chromium and / or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and / or neurodegenerative disorders, and / or raising HDL cholesterol and / or lean body mass in humans and animals. The method comprises administering policosanol and chromium and / or chromium salts which together effectively lower blood glucose levels and lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and / or chromium salts.

To provide a method of lowering blood glucose levels and a method of treating and preventing diabetes. A belt-shaped compression strip 1 is fitted around a tightened area near the proximal end of an arm or a leg of a user and is fastened round the area. In this way, a compression pressure of on the order of 150 mmHg is applied to the tightened area to restrict blood flow through limbs receiving the compression pressure. This condition is held for about 15 minutes. During that time a user may keep rest or may do light exercises, which lowers a blood glucose level of the user. This provides treatment for diabetes for a diabetes patient and provides prevention of diabetes for a person who has a risk of developing diabetes.

The invention provides a preparation method and application of physiologically active notoginseng polysaccharide. The method comprises the steps of refining and purifying by applying resin column chromatography, activated carbon and membrane separation and purification technology, and the like, so as to obtain the notoginseng polysaccharide. The notoginseng polysaccharide obtained by the preparation method provided by the invention has the characteristics of low protein, heavy metal and ash contents and stable quality, has the physiological activities of immunity regulation, liver injury protection, blood glucose decrease, tumor resisting and the like, and can be used singly or combined as raw materials for natural medicines and health products. The preparation method of the notoginseng polysaccharide, provided by the invention, is simple to operate, applicable for industrial production and low in cost and reaches the purposes of energy saving and consumption reduction and realizing comprehensive development and sustainable utilization of the rare Chinese traditional medicine, namely, notoginseng.

The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21 ) compound and a Glucagon-Like Peptide 1 (GLP-1 ) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of [beta] cells ex vivo in the presence of free fatty acids, on caspase activity of [beta] cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db / db mice in vivo.

A method for treating hyperglycemia and / or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

A reducer of blood glucose level increase comprising palatinose as an active ingredient, wherein the reducer is ingested before or after or simultaneously with consuming a carbohydrate having an alpha-1, 6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides to reduce an increase in blood glucose level caused by ingesting the carbohydrate.

The invention discloses bolete extracting solution and beverages, belonging to the field of edible fungi beverages. The preparation method of the bolete extracting solution comprises the following steps of: extracting crushed bolete dry powder or fresh bolete slurry in water, then filtering to obtain filtrate, centrifuging the filtrate, and collecting supernate. By utilizing the bolete extracting solution, different flavors of bolete beverages can be prepared. The bolete beverage has rich nutrient components and simultaneously contains a great deal of polysaccharides with the functions of improving body immunity, reducing the blood sugar levels and cholesterol, resisting the ageing, and the like; secondly, the invention is convenient to carry and ready to drink and solves the problem that fresh bolete is difficult to store and transport; the invention can be also used as raw materials of beverages and food processing and prepared into different flavors of beverages; and besides, the invention has simple method, low cost and no environmental pollution.

The invention relates to a solid beverage having an assisted blood glucose lowering function, and a preparation method thereof, wherein the main function components are three or more than three materials selected from kelp or a kelp extract, potassium alginate (low molecular weight potassium alginate), common yam rhizome or a common yam rhizome extract, Chinese wolfberry or a Chinese wolfberry extract, radix puerariae or a radix puerariae extract, mulberry leaf or a mulberry leaf extract, a polygonatum odoratum extract, a bitter gourd extract, the leaf of cyclocarya paliurus and corn stigma, the auxiliary materials comprise one or more than one materials selected from inulin, resistant dextrin, bean powder, tea powder, pumpkin powder, soybean protein powder, barley leaf powder, oat fiber powder, konjac powder and citrus fiber powder, and the flavoring agent is one or a plurality of materials selected from stevioside, xylitol, fructo oligosaccharide, isomaltitol, sucralose, trehalose, matcha powder, and fruit and vegetable powder. The preparation method comprises: 1, crushing, and screening; 2, weighing; 3, carrying out mixing stirring, or carrying out stirring mixing and granulation; and 4, packaging. The solid beverage of the present invention has advantages of significant blood glucose lowering effect, good safety, and no side effect.

The present invention provides a blood glucose-lowering health-care product and the preparation method thereof, wherein the health-care product comprises components with the shares in weight as follows respectively: sealwort (30 to 40 shares), yam (30 to 44 shares), and kudzu root (30 to 38 shares), and the preparation method of the blood glucose-lowering health-care product includes the procedures as follows: a. prepare the raw materials as above based on the weight shares, and then, b. each material is made into fine powder, filtrated and then, c. all raw materials are mixed, weighed, and encapsulated. The health-care product provided by the present invention has reliable health-care effect without any side effect, and has high nutritional value, capability to tonify Qi, improve and adjust the organic immunity, with outstanding effect to lower the blood glucose.

The invention discloses an exendin-4 analogue.Under stimulation of the analogue, islet cell tumor cells INS-1 of a rat can secrete insulin significantly more actively than that under the simulation of wild exendin-4, and hypoglycemic activity in the body of a diabetic model mouse C57B L / KsJ-db / db is significantly better than that under the simulation of wild exendin-4; the exendin-4 analogue is useful to prevent, treat or alleviate diabetics and obesity as well as other diseases benefiting from glucose reduction, gastrointestinal activity inhibition and gastric emptying.

The invention provides a cultivation method of lucid ganoderma for reducing blood sugar. In the method, a Chinese medicinal herbal composition for reducing the blood sugar in a certain rate is added into a culture base stock, so that nutrient components in the culture base stock are fully absorbed by the lucid ganoderma in the growth and development process; therefore, the cultivated lucid ganoderma has the effect of efficiently reducing the blood sugar, medicines for reducing the blood sugar can be completely replaced, various complications brought to a patient by the medicines for reducing the blood sugar are greatly reduced, and the quality of life of the patient is improved.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

A feungreek extract containing the common saponin of feungreek for preventing and treating diabetes and its chronic complications is prepared through extracting with alcohol, macroreticular adsorption, washing for removing impurities, eluting, concentrating the eluting liquid, and drying.